Quest is the first lab to offer the laboratory test based on the Septin9 marker. The test is called the “ColoVantage” test and is not considered a screening test but patients may consider the test as it is less evasive than some of the current tests.
In other related Quest news, one of their employees participated on the TV show “The Biggest Loser” so he’s serving to set an example for other in the company for losing weight. BD
A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated (NYSE: DGX). The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.
The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG, a cancer molecular diagnostics company. Quest Diagnostics is the first commercial laboratory in the U.S. to offer a laboratory-developed test based on the Septin9 biomarker.The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cancer that was identified by Epigenomics AG, a cancer molecular diagnostics company. Quest Diagnostics is the first commercial laboratory in the U.S. to offer a laboratory-developed test based on the Septin9 biomarker.
"Early detection rates are dismally low, largely because many patients find existing tests and procedures invasive or unpleasant," said Jon R. Cohen, M.D. senior vice president and chief medical officer, Quest Diagnostics. "Our ColoVantage™ test, which is based on Septin9, has yet to be clinically validated as a screening test. Rather, it may promote further evaluation in patients who have resisted testing in the past or as an adjunct to existing procedures."
From this explanation , one can readily visualize how DNA Methylation is grow and its different roles in the immune system.Really it is so informatice to all.
ReplyDelete